RecruitingPhase 2Phase 3NCT06477536

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis

Sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.

Enrollment

33 participants

Start Date

Sep 2, 2024

Study Type

INTERVENTIONAL

Conditions

Generalized Pustular Psoriasis

Summary

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HB0034 for people with generalized pustular psoriasis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHB0034

300mg, i.v. Q4W

Locations(3)

Peking University People's Hospital (PKUPH)

Beijing, China

Peking University People's Hospital

Beijing, China

The Second affiliated Hospital zhejiang University School of Medicine

Hangzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06477536

Related Trials

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

NCT0731406032 locations

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

NCT061009911 location